Skip to main content
VIYASH SCIENTIFIC LIMITED logo

VIYASH SCIENTIFIC LIMITED — Investor Relations & Filings

Ticker · VIYASH ISIN · INE807F01027 LEI · 335800SXM7D3VSHF2X07 BSE.NS Manufacturing
Open in API
Filings indexed 1,420 across all filing types
Latest filing 2026-02-05 Regulatory Filings
Country IN India
Listing BSE.NS VIYASH

About VIYASH SCIENTIFIC LIMITED

https://www.viyash.com

Viyash Scientific Limited is an integrated pharmaceutical platform specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage forms. The organization operates a network of manufacturing facilities supported by robust research and development capabilities, focusing on complex chemistry and niche therapeutic segments. Its core business activities encompass the entire pharmaceutical value chain, from process development and scale-up to commercial-scale production. The company provides integrated solutions to global partners, leveraging its technical expertise in chemical synthesis and commitment to international quality standards. By maintaining a focus on operational excellence and innovation, the company serves as a strategic partner in the global healthcare supply chain, delivering high-quality medicinal components and formulations.

Recent filings

Filing Released Lang Actions
Unaudited standalone and Consolidated Results for Q3 FY 26
Regulatory Filings
2026-02-05 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 90% confidence The document is a securities exchange filing under SEBI Listing Regulations announcing the outcome of a Board meeting and including the unaudited standalone and consolidated financial results for the quarter and nine-month period ended December 31, 2025, together with an Independent Auditor’s Limited Review Report. It contains detailed interim financial statements, not merely a link or announcement, and is not a high-level earnings summary. Therefore it qualifies as an Interim/Quarterly Report. 9M 2025
2026-02-05 English
Outcome of Board Meeting held on Thursday, February 05, 2026, along with Unaudited Standalone & Consolidated Financial Results for the quarter and nine months ended December 31, 2025.
Regulatory Filings
2026-02-05 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a notification to stock exchanges about the rescheduling of a conference call to discuss the company's Q3FY26 financial results. It includes details about the call timing, speakers, and dial-in information. The document does not contain actual financial data or a transcript of the call, but rather serves as an announcement or update about the conference call event. Therefore, it fits the category of a Call Transcript announcement or update. Since it is an announcement of the conference call and not the transcript itself, the best fitting category is Call Transcript (CT). Confidence is high given the clear context and content.
2026-02-03 English
Intimation of Conference call - rescheduled at 5:30 p.m. (IST), on Friday, February 06, 2026
Call Transcript Classification · 90% confidence The document is a notification to stock exchanges about the rescheduling of a conference call to discuss the company's Q3FY26 financial results. It includes details about the call timing, speakers, and dial-in information. The document does not contain actual financial data or analysis but is an announcement related to an upcoming earnings call. Therefore, it is not the earnings release itself nor the transcript but an update/intimation about the conference call. Given the content and purpose, the most appropriate classification is Call Transcript (CT) category, as it relates directly to a conference call event. However, since this is only an intimation of the call and not the transcript, the best fit is still CT because the document is about the conference call event. Confidence is high due to clear references to the conference call and Q3FY26 earnings discussion.
2026-02-03 English
General Updates
Share Issue/Capital Change Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the allotment of equity shares under an Employee Stock Option Plan (ESOP). It details the number of shares allotted, the exercise price, and the resulting change in the company's paid-up equity share capital. There is no financial statement or detailed financial analysis present. The document is an announcement of a capital change related to share allotment. According to the filing definitions, announcements regarding new share issues or capital changes fall under the category 'Share Issue/Capital Change' (SHA). The document length is short and it is not a report or a certification, so it is not an Annual Report, Interim Report, or Regulatory Filing. Therefore, the correct classification is SHA with high confidence.
2026-01-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.